NCT06346509

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 108 (estimated)
• Sponsor: Portal Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.

Conditions

• Healthy Adult Participants

Interventions

Type	Name	Description
DRUG	PORT-77	Healthy adult participants will receive a single oral dose of PORT 77.
DRUG	Placebo	Healthy adult participants will receive matching placebo on Day 1.

Timeline

• Start date: 2024-04-08
• Primary completion: 2025-08-29
• Completion: 2025-08-29
• First posted: 2024-04-04
• Last updated: 2025-04-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study